Schizophrenia Clinical Trial
Official title:
An Open Label, Randomised, Three-way Cross-over Study to Evaluate the Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy Male and Female Subjects
GSK1144814 is a potent, insurmountable antagonist at human neurokinin-1 (NK1) and
neurokinin-3 (NK3) receptors with the potential to treat multiple symptom domains of
schizophrenia and be an efficacious antidepressant.
This study will be an open label, randomised, three-way cross-over study to evaluate the
safety, tolerability and pharmacokinetics of a new tablet formulation of GSK1144814 and to
evaluate the effect of food on single oral doses of GSK1144814 in healthy male and female
subjects.
GSK1144814 is a potent, insurmountable antagonist at human neurokinin-1 (NK1) and
neurokinin-3 (NK3) receptors with the potential to treat multiple symptom domains of
schizophrenia and be an efficacious antidepressant.
This study will be an open label, randomised, three-way cross-over study to evaluate the
safety, tolerability and pharmacokinetics of a new tablet formulation of GSK1144814 and to
evaluate the effect of food on single oral doses of GSK1144814 in healthy male and female
(non-child bearing potential) subjects.
The study will consist of a Screening visit (up to 30 days before the first dosing session),
three dosing sessions each separated by a maximum of at least 6 days washout, and a Follow
up visit (7 to 14 days after the last dose of study medication). Each subject's
participation in the study will be approximately 12 weeks Sixteen subjects will be enrolled
to provide a minimum number of 12 evaluable subjects. The doses to be administered will be
100 mg and 200mg in the fasted state, and 100mg following a high fat breakfast.
Subjects will be admitted to the unit on Day 1 of each dosing session and will remain in the
unit until 48 hours after dosing. Pharmacokinetic samples will be taken for up to 72 hours
post dose. The duration of both in patient stay and PK sampling may be subject to change
depending on emerging safety and PK results. Dosing will be in the morning approximately the
same time for all sessions.
The objectives of the study are to evaluate the pharmacokinetics, safety and tolerability of
GSK1144814. Pharmacokinetic objectives are to evaluate the pharmacokinetic parameters of
single oral doses of GSK1144814 administered as a tablet formulation in healthy male and
female subjects and to evaluate the effect of a high-fat meal on the pharmacokinetics of
GSK1144814 tablet following single dose administration of GSK1144814 to healthy male and
female subjects.
The safety and tolerability objectives are to evaluate the safety and tolerability of single
oral doses of GSK1144814 tablet formulation in fed and fasted states.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
| Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
| Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
| Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
| Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
| Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
| Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
| Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
| Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
| Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
| Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
| Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
| Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
| Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
| Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
| Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
| Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
| Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |